Search
Physician-scientist Michael S. Glickman specializes in the treatment and study of infectious diseases.
MSK-ACCESS, a blood test that can detect mutations in 129 genes related to cancer, has already helped guide the treatment of more than 2,800 patients at MSK.
Research led by investigators at Memorial Sloan Kettering Cancer Center has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson's disease in mice.
Cancer DNA taken from spinal fluid could serve as a liquid biopsy that provides information on brain tumor mutations.
By assuming primitive regenerative identities, cancer cells gain the adaptability they need to establish tumors in new parts of the body.
Research led by investigators at Memorial Sloan Kettering has identified a previously unknown mechanism of resistance to the newly approved melanoma drug, vemurafenib.
Immunologist Alexander Rudensky and medical oncologist and immunologist Jedd Wolchok are investigating innovative ways to use the immune system to fight cancer.
GSK students, alumni, faculty, and guest speakers enjoyed two days of presentations, panel discussions, a poster session, recreation and socializing at the school’s fourth biennial retreat.
Targeting the cancer environment, rather than the cancer itself, could be a new avenue for immunotherapy.
A recent Memorial Sloan Kettering study shows that some circulating tumor cells can circle back and infiltrate their tumor of origin, enhancing its growth and aggressiveness.